Barclays maintains Tenet Healthcare at Overweight, raises price target to $297 from $271
Barclays kept Tenet Healthcare's rating at Overweight and increased its price target to $297 from $271, suggesting an 11.4% upside from the Nov 3 close of $266.69. Recent analyst price targets for the company range from $300 to $342.
How this was made

The 30-second read
Why it matters
The upgrade may attract institutional buying and support the stock price.
Market read
A fresh analyst target can influence short‑term price action for TEN.
What to watch
No new operational data; price move depends on broader market sentiment.
Background
Barclays maintains an Overweight rating on Tenet Healthcare, updating its valuation.
Market effects
May lift sentiment in the healthcare services sector.
US healthcare stocks could see modest gains.
Limited to US markets.
Counterpoint
Target raise could be premature if earnings miss expectations.
Key entities
- analystBarclays
Equity research firm providing the rating and target.
- companyTenet Healthcare
U.S. healthcare services provider.


